In a study of 15 patients with histologically proven nodular BCC, 9 of whom were treated with intralesional IFN-α-2b, the BCC cells of untreated patients constitutively expressed CD95L, whereas the BCC cells of treated patients not only expressed CD95L but also became CD95 positive. This evidence concerns the gene IFNA2 and skin basal cell carcinoma.